Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T

Alana L. Keller, Sarah E. Parzych, Lauren T. Reiman, Zachary J. Walker, Peter A. Forsberg, Daniel W. Sherbenou

Blood (2023) 142 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2023-187385

Published: 2023

Journal Articles

High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Alana Keller, Olivia Perez De Acha, Lauren T Reiman, Zachary J Walker, David S Jayabalan, Ruben Niesvizky, Peter A Forsberg, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Blood (2022) 140 (Supplement 1): 7097–7099.

https://doi.org/10.1182/blood-2022-169072

Published: 2022

Journal Articles

Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia

Mohd Minhajuddin, Haobin Ye, Amanda C. Winters, Shanshan Pei, Nabilah Khan, Brett M. Stevens, Biniam Adane, Maria L. Amaya, Anagha Inguva, Anna Krug, Maura Gasparetto, Daniel W. Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T. Jordan

Blood (2021) 138 (Supplement 1): 630.

https://doi.org/10.1182/blood-2021-151400

Published: 2021

Journal Articles

Prolonged Omacetaxine Treatment Alters Fitness and Proteostasis in Multiple Myeloma

Zachary J Walker, Rachel N Steinmetz, Denis J Ohlstrom, Lauren T Reiman, Taylor S Mills, Beau M Idler, Brett M. Stevens, Eric Pietras, Daniel W. Sherbenou

Blood (2021) 138 (Supplement 1): 1604.

https://doi.org/10.1182/blood-2021-151953

Published: 2021

Journal Articles

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Beau M Idler, Olivia Perez De Acha, MD, Owen Lockerbie, PhD, Ken Flanagan, PhD, Fredrik Lehmann, MSc, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Daniel W. Sherbenou, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138762

Published: 2020

Journal Articles

Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients

Olivia Perez De Acha, MD, Beau M Idler, Zachary J Walker, BS, MS, Peter A Forsberg, MD, Tomer M Mark, MD MS, Daniel W. Sherbenou, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137819

Published: 2020

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

Prashant Sharma, MD, Enkhtsetseg Purev, MD PhD, Bradley M. Haverkos, MD MPH, MS, Daniel A Pollyea, MD, Clayton Smith, MD, Manali Kamdar, Daniel W Sherbenou, MD PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 4660.

https://doi.org/10.1182/blood-2018-99-119690

Published: 2018

Journal Articles

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Zachary J Walker, MS, Michael J VanWyngarden, BS, Brett M Stevens, PhD, Christophe Langouët-Astrie, MS, Clayton Smith, MD, Brent E Palmer, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Craig T Jordan, PhD, Daniel W Sherbenou, MD PhD

Blood (2018) 132 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2018-99-111394

Published: 2018

Journal Articles

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MDMSc, Daniel W. Sherbenou, MDPhD, Andrew Hammes, MS, Adriana C. Rossi, MDMSc, Ruben Niesvizky, MD, David S Jayabalan, MSc, Scott Ely, MDMPH

Blood (2017) 130 (Supplement 1): 3059.

https://doi.org/10.1182/blood.V130.Suppl_1.3059.3059

Published: 2017

Journal Articles

Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes

Zohra Nooruddin, MD, Zenggang Pan, MD PhD, Lilyana Gross, Weitzenkamp David, Bradley M. Haverkos, MD MPH, MS, Daniel A Pollyea, MD, Jonathan A Gutman, MD, William Robinson, MD PhD, Clayton Smith, MD FRCPC, Jeffrey Schowinsky, MD, Purev Enkhtsetseg, MD, Daniel W. Sherbenou, MD PhD, Rachel Rabinovitch, MD, Douglas Ney, MD, Craig T Jordan, PhD, Manali Kamdar, MD

Blood (2016) 128 (22): 3054.

https://doi.org/10.1182/blood.V128.22.3054.3054

Published: 2016

Journal Articles

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Daniel W. Sherbenou, MD PhD, Blake T. Aftab, PhD, Yang Su, PhD, Christopher R. Behrens, PhD, Arun P. Wiita, MD PhD, Aaron C. Logan, MD PhD, Diego Acosta-Alvear, PhD, Byron C. Hann, MD PhD, Peter Walter, PhD, Xiaobo Wu, MD, John P. Atkinson, MD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Bin Liu, PhD

Blood (2016) 128 (22): 384.

https://doi.org/10.1182/blood.V128.22.384.384

Published: 2016

Journal Articles

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Daniel W. Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm, Lalita P. Turaga, Thoralf Lange, Kim-Hien Dao, Richard D. Press, Brian J. Druker, Giulio Superti-Furga, Michael W. Deininger

Blood (2010) 116 (17): 3278–3285.

https://doi.org/10.1182/blood-2008-10-183665

Published: 2010

Includes: Supplemental data

Journal Articles

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

Daniel W. Sherbenou, BA, Oliver J. Hantschel, PhD, Lalita Turaga, BS, Ines Kaupe Mag, Stephanie Willis, BS, Thomas Bumm, MD, Richard D. Press, MD, PhD, Giulio Superti-Furga, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2007) 110 (11): 2936.

https://doi.org/10.1182/blood.V110.11.2936.2936

Published: 2007

Journal Articles

A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression.

Daniel W. Sherbenou, BA, Oliver Hantschel, PhD, Stephanie Willis, BS, Richard D. Press, MD, Brian J. Druker, MD, Giulio Superti-Furga, PhD, Michael W. Deininger, MD, PhD

Blood (2006) 108 (11): 2188.

https://doi.org/10.1182/blood.V108.11.2188.2188

Published: 2006

Journal Articles

JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice.

Thomas G.P. Bumm, MD, Collin Elsea, Lisa G. Wood, RN, PhD, Daniel W. Sherbenou, Ian J. Griswold, PhD, Marc Loriaux, MD, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2005) 106 (11): 376.

https://doi.org/10.1182/blood.V106.11.376.376

Published: 2005

Journal Articles

In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.

Daniel W. Sherbenou, Matthew J. Wong, Adil Humayun, Laura S. McGreevey, Rui Yang, MD, Michael C. Heinrich, MD, Richard D. Press, MD, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2005) 106 (11): 434.

https://doi.org/10.1182/blood.V106.11.434.434

Published: 2005

NARROW

BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T

High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia

Prolonged Omacetaxine Treatment Alters Fitness and Proteostasis in Multiple Myeloma

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression.

JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice.

In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only